the same effect. There will always be some uncertainty surrounding estimates of treatment effects, and a small difference can never be excluded" (3) .
A solution to both this incompatibility (between 1-sided clinical reasoning and 2-sided statistical testing) and confusion (about the clinical interpretation of statistically nonsignificant results) has been around for decades but is just now gaining widespread recognition and application. I assign most of the credit to a pair of biostatisticians, Charles Dunnett and Michael Gent (others have also contributed to its development [4] , although they sometimes refer to "noninferiority" as "equivalence," a term whose common usage fails to distinguish 1-sided from 2-sided thinking). I'll illustrate Charlie Dunnett's and Mike Gent's contribution with a pair of trials in which their thinking helped clinical colleagues escape from the prison of 2-sided null hypothesis testing and, by doing so, prevented the misinterpretation of statistically nonsignificant results (5) .
Thirty years ago, a group of us performed a randomized controlled trial (RCT) of nurse practitioners as providers of primary care (6) . We wanted to know if patients fared as well under their care as under the care of general practitioners. Guided by Mike Gent, we came to realize that a 2-sided analysis that produced an "indeterminate," statistically nonsignificant difference in patient outcomes could confuse rather than clarify matters. We therefore abandoned our initial 2-sided null hypothesis and decided that we'd ask a noninferiority question: Were the outcomes of patients cared for by nurse practitioners noninferior to those of patients cared for by general practitioners? Mike Gent then helped us recognize the need to specify our limit of acceptable "inferiority" in terms of these outcomes. With his prodding, we decided that we would tolerate no worse than 5% lower physical, social, or emotional function at the end of the trial among patients randomized to our nurse practitioners as we observed among patients randomized to our general practitioners. As it happened, our 1-sided analysis revealed that the probability that our nurse practitioners' patients were worse off (by ≥ 5%) than our general practitioners' patients was as small as 0.008. We had established that nurse practitioners were not inferior to general practitioners as providers of primary care.
Twenty years ago, a group of us performed an RCT of superficial temporal artery-middle cerebral artery anastomosis ("EC-IC bypass") for patients with threatened stroke (7) . To the disappointment of many, we failed to show a statistically significant superiority of surgery for preventing subsequent fatal and nonfatal stroke. It became important to overcome the ambiguity of this "indeterminate" result. We therefore asked the 1-sided question: What degree of surgical benefit could we rule out? That 1-sided analysis, which calculated the upper end of a 90% (rather than a 95%) confidence interval, excluded a surgical benefit as small as 3%. When news of this 1-sided result got around, performance of this operation rapidly declined.
Thanks to statisticians like Charlie Dunnett and Mike Gent, we now know how to translate rational, 1-sided clinical reasoning into sensible, 1-sided statistical analysis. Moreover, this modern strategy of asking 1-sided noninferiority and superiority questions in RCTs is gathering momentum. The CONSORT statement on recommendations for reporting RCTs omits any requirement for 2-sided significance testing. Even some journal editors are getting the message, for 1-sided noninferiority and superiority trials have now appeared in the New England Journal of Medicine (8) , Lancet (9), and JAMA (10) , and this issue of ACP Journal Club includes another Lancet article (2) (see Ximelagatran was nonin-ferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation).
An essential prerequisite to doing 1-sided testing is the specification of the exact noninferiority and superiority questions before the RCT begins. As with unannounced subgroup analyses, readers can and should be suspicious of authors who apply 1-sided analyses without previous planning and notice. Have they been slipped in only after a peek at the data revealed that conventional 2-sided tests generated indeterminate results? This need for prior specification of 1-sided analyses provides yet another argument for registering RCTs in their design stages and for publishing their protocols in open-access journals such as Biomed Central (www.biomedcentral.com).
I hope that this editorial will help free front-line clinicians, investigators, and editors from the 2-sided null-hypothesis prison. If any traditional, 2-sided biostatisticians happen upon it, they may object. If their objections are relevant to this journal's readers, they might appear in these pages.
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